Q-omics provides the consensus-scored ETV4 profile across patient tissues and cancer cell-line models. ETV4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ETV4 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, ETV4 RNA expression shows 18,120 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where ETV4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ETV4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ETV4 survival associations across molecular data types. ETV4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ETV4 RNA expression–survival associations across cancer types. High ETV4 expression shows unfavorable associations in ACC, MESO, LIHC, KIRC and LGG, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ETV4 RNA expression.
This table summarizes ETV4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ETV4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ETV4 shows lower tumor expression in KIRC and higher tumor expression in COAD, THCA, BLCA, LUAD and STAD. The COAD box plot shows higher ETV4 RNA expression in tumor versus normal tissue (log2 FC = +5.394, t-test p < 0.001).
This table shows molecular features associated with ETV4 in patient tissues and cancer cell lines. In patient samples, ETV4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ETV4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
